← Back to Clinical Trials
Recruiting NCT07373418

NCT07373418 Glucose Observation and Wearable Use for Prevention

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07373418
Status Recruiting
Phase
Sponsor University of St.Gallen
Condition Prevention
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2025-12-08
Primary Completion 2027-01

Eligibility & Interventions

Sex All sexes
Min Age 45 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2025-12-08 with a primary completion date of 2027-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The GLOW UP study is a single-center, prospective, observational case-control study conducted in St. Gallen, Switzerland. The primary aim of the study is to examine to what degree lifestyle data collected from wearable devices and a smartphone app can identify individuals with prediabetes (vs. normoglycemic) in a real-world setting. The study also aims to characterize variability in lifestyle and glycemic patterns and to examine how between- and within-person differences relate to diabetes risk; to identify personalized predictors of early metabolic dysregulation. The study also evaluates new image-based meal tracking algorithms for predicting glycemic control and examines how reminder messages influence adherence to a \~4-week meal logging protocol. The study aims to enroll 200 adults aged 45 years and older with a BMI of at least 25 kg/m² and no known diagnosis of diabetes, including 100 participants with prediabetes and 100 normoglycemic (metabolically healthy) controls. Participants will be classified at the baseline visit using HbA1c and fasting plasma glucose (FPG) tests, with prediabetes defined as HbA1c 5.7-6.4% and/or FPG 5.6-6.9 mmol/L, and normoglycemia defined as HbA1c \<5.7% and FPG \<5.6 mmol/L, following clinical standards. During the \~4-week observational period, participants will be asked to wear a smart ring, a wrist-worn smartwatch, and a blinded continuous glucose monitor (CGM). Participants will be asked to log/take-images of their meals via a study app and to complete brief questionnaires (e.g., tracking mood, stress, and contextual meal annotations) via ecological momentary assessments. FPG and HbA1c samples will be collected at baseline to classify participants as prediabetic or normoglycemic, and again at follow-up (\~4 weeks), which will serve as the primary outcome to evaluate associations between lifestyle and wearable-derived data and diabetes risk status.

Eligibility Criteria

Inclusion Criteria: * Citizens or residents of Switzerland who are German-speaking (main place of living or employment in Switzerland). * Age ≥45 years. * BMI ≥25 kg/m² (overweight or obese). * Regular access to a smartphone (iOS or Android) with a data plan. * Able to use smartphone applications. * Able to walk independently. Exclusion Criteria: * History of stroke, heart disease, renal failure, cancer, or diabetes (type 1 or type 2). * Past vascular bypass surgery or angioplasty. * Current or planned use of glucose-lowering medications during the upcoming 4 weeks (e.g., GLP-1 receptor agonists, metformin). * Pregnant or breastfeeding. * Relevant skin conditions at wearable placement sites (e.g., upper arm). * BMI \<25 kg/m² confirmed at enrollment. * FPG ≥7.0 mmol/L and/or HbA1c ≥6.5% (newly identified type 2 diabetes); Individuals who meet type-2 diabetes criteria at enrollment, based on Swiss/ADA diagnostic criteria will be informed of blood test results and referred to a GP. These individuals will be deemed ineligible and excluded from the study.

Contact & Investigator

Central Contact

Mia Jovanova, Dr.

✉ mia.jovanova@unisg.ch

📞 +41 44 632 05 41

Frequently Asked Questions

Who can join the NCT07373418 clinical trial?

This trial is open to participants of all sexes, aged 45 Years or older, studying Prevention. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07373418 currently recruiting?

Yes, NCT07373418 is actively recruiting participants. Contact the research team at mia.jovanova@unisg.ch for enrollment information.

Where is the NCT07373418 trial being conducted?

This trial is being conducted at Sankt Gallen, Switzerland.

Who is sponsoring the NCT07373418 clinical trial?

NCT07373418 is sponsored by University of St.Gallen. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology